Meta-analysis finds comparable safety profiles between bevacizumab and ranibizumab

Using data from 5 multicenter randomized trials, investigators compared the risk of systemic adverse events associated with ranibizumab and bevacizumab for treatment of neovascular AMD.
Source: Daily Dose of Eye Care

https://www.lvcenter4sight.com/meta-analysis-finds-comparable-safety-profiles-between-bevacizumab-and-ranibizumab/

Comments

Popular posts from this blog

FDA Authorizes Clinical Trial for CRISPR/Cas9 Therapy for LCA 10

Cataract Surgery Leads to Longer Life in Women

Vision Improvements Reported in ProQR’s Clinical Trial for LCA10 Treatment